Area of research
Cardiology and Cardiovascular Medicine · Endocrinology, Diabetes and Metabolism
Research interest
Research interests include Heart Failure Treatment and Management, Cardiovascular Function and Risk Factors, Diabetes Treatment and Management, and Cardiomyopathy and Myosin Studies.
Large-scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy
Mechano-energetic uncoupling in heart failure
EuroQol 5-Dimension Questionnaire in Heart Failure With Reduced, Mildly Reduced, and Preserved Ejection Fraction
Chronic kidney disease and incident cancer risk: an individual participant data meta-analysis
Severe Heart Failure and Treatment With Dapagliflozin Across the Ejection Fraction Spectrum
Efficacy and Safety of CDR132L in Patients with Reduced Left Ventricular Ejection Fraction After Myocardial Infarction: Rationale and Design of the HF-REVERT Trial
Cardiovascular Toxicities of Immune Therapies for Cancer – A Scientific Statement of the Heart Failure Association (HFA) of the ESC and the ESC Council of Cardio-Oncology
Prognostic Models for Mortality and Morbidity in Heart Failure With Preserved Ejection Fraction
Heart failure pharmacotherapy and cancer: pathways and pre-clinical/clinical evidence
Dapagliflozin and Mode of Death in Heart Failure With Improved Ejection Fraction
Beta-Blocker Use and Outcomes in Patients with Heart Failure and Mildly Reduced and Preserved Ejection Fraction
Long-term reliability of the phospholamban (PLN) p.(Arg14del) risk model in predicting major ventricular arrhythmia: a landmark study
Remote haemodynamic monitoring of pulmonary artery pressures in patients with chronic heart failure (MONITOR-HF): a randomised clinical trial
Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid–Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout
The Cardioprotective Effects of Semaglutide Exceed Those of Dietary Weight Loss in Mice With HFpEF
Multiomics Analysis Provides Novel Pathways Related to Progression of Heart Failure
Efficacy of pulmonary artery pressure monitoring in patients with chronic heart failure: a meta-analysis of three randomized controlled trials
Dapagliflozin and diuretic utilization in heart failure with mildly reduced or preserved ejection fraction: the DELIVER trial
Dapagliflozin in Patients With Heart Failure and Deterioration in Renal Function
Contemporary Use and Implications of Beta-Blockers in Patients With HFmrEF or HFpEF
Priorities in Cardio-Oncology Basic and Translational Science
Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities
Association of Initial and Longitudinal Changes in C-reactive Protein With the Risk of Cardiovascular Disease, Cancer, and Mortality
Cardio-Renal-Metabolic Overlap, Outcomes, and Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Evaluation of Senescence and Its Prevention in Doxorubicin-Induced Cardiotoxicity Using Dynamic Engineered Heart Tissues
Relative fat mass and prediction of incident atrial fibrillation, heart failure and coronary artery disease in the general population
Heart failure, peripheral artery disease, and dapagliflozin: a patient-level meta-analysis of DAPA-HF and DELIVER
Outpatient Worsening Among Patients With Mildly Reduced and Preserved Ejection Fraction Heart Failure in the DELIVER Trial
Incidence, Risk Assessment and Prevention of Sudden Cardiac Death in Cardiomyopathies